JP2017535610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535610A5 JP2017535610A5 JP2017545520A JP2017545520A JP2017535610A5 JP 2017535610 A5 JP2017535610 A5 JP 2017535610A5 JP 2017545520 A JP2017545520 A JP 2017545520A JP 2017545520 A JP2017545520 A JP 2017545520A JP 2017535610 A5 JP2017535610 A5 JP 2017535610A5
- Authority
- JP
- Japan
- Prior art keywords
- carbons
- compound according
- linear
- compound
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 82
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 125000002947 alkylene group Chemical group 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 239000005977 Ethylene Substances 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 11
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 10
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- -1 alkynyl carbon Chemical compound 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- QQONPFPTGQHPMA-UHFFFAOYSA-N propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 206010027665 Immune disorder Diseases 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 230000003176 fibrotic Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/546,105 | 2014-11-18 | ||
US14/546,105 US9593077B2 (en) | 2013-11-18 | 2014-11-18 | Ionizable cationic lipid for RNA delivery |
US14/707,796 | 2015-05-08 | ||
US14/707,876 | 2015-05-08 | ||
US14/707,876 US9365610B2 (en) | 2013-11-18 | 2015-05-08 | Asymmetric ionizable cationic lipid for RNA delivery |
US14/707,796 US9567296B2 (en) | 2013-11-18 | 2015-05-08 | Ionizable cationic lipid for RNA delivery |
PCT/US2015/030218 WO2016081029A1 (en) | 2014-11-18 | 2015-05-11 | Ionizable cationic lipid for rna delivery |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017535610A JP2017535610A (ja) | 2017-11-30 |
JP2017535610A5 true JP2017535610A5 (US20080131398A1-20080605-C00009.png) | 2018-09-27 |
JP6637988B2 JP6637988B2 (ja) | 2020-01-29 |
Family
ID=56014367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017545520A Active JP6637988B2 (ja) | 2014-11-18 | 2015-05-11 | Rna送達のためのイオン化可能カチオン性脂質 |
Country Status (20)
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6486955B2 (ja) | 2013-11-18 | 2019-03-20 | アークトゥルス セラピューティクス, インコーポレイテッド | Rna送達のためのイオン化可能なカチオン性脂質 |
WO2018112282A1 (en) | 2016-12-14 | 2018-06-21 | Ligandal, Inc. | Compositions and methods for nucleic acid and/or protein payload delivery |
WO2018119163A1 (en) * | 2016-12-21 | 2018-06-28 | Payne Joseph E | Ionizable cationic lipid for rna delivery |
US10383952B2 (en) * | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
WO2018183901A1 (en) * | 2017-03-30 | 2018-10-04 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines |
US20230149310A1 (en) * | 2018-03-30 | 2023-05-18 | Arcturus Therapeutics, Inc. | Lipid particles for nucleic acid delivery |
ES2960936T3 (es) | 2018-04-25 | 2024-03-07 | Ethris Gmbh | Formulaciones a base de lípidos para el suministro de ARN |
KR20190127277A (ko) * | 2018-05-04 | 2019-11-13 | 주식회사 삼양바이오팜 | mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법 |
CA3102985C (en) | 2018-06-08 | 2023-03-28 | Fujifilm Corporation | Compound or salt thereof and lipid particles |
CA3122080A1 (en) | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
AU2020241756A1 (en) | 2019-03-19 | 2021-11-04 | Arcturus Therapeutics, Inc. | Method of making lipid-encapsulated RNA nanoparticles |
CN113924128A (zh) | 2019-06-07 | 2022-01-11 | 富士胶片株式会社 | 脂质组合物 |
WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
CN114728016A (zh) | 2019-11-15 | 2022-07-08 | 富士胶片株式会社 | 脂质组合物 |
WO2021195214A1 (en) | 2020-03-24 | 2021-09-30 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
CA3172591A1 (en) | 2020-03-24 | 2021-09-30 | Douglas Anthony KERR | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
EP4211247A1 (en) | 2020-09-13 | 2023-07-19 | Arcturus Therapeutics, Inc. | Lipid nanoparticles encapsulation of large rna |
KR20240012370A (ko) | 2021-04-20 | 2024-01-29 | 안자리움 바이오사이언시스 아게 | 아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법 |
WO2022232286A1 (en) | 2021-04-27 | 2022-11-03 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
WO2022232289A1 (en) | 2021-04-27 | 2022-11-03 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
CA3236235A1 (en) | 2021-11-08 | 2023-05-11 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
CN114213295B (zh) * | 2022-02-22 | 2022-05-20 | 中国科学院基础医学与肿瘤研究所(筹) | 一种阳离子化合物、制备方法及其复合物和用途 |
WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
WO2024064910A1 (en) | 2022-09-23 | 2024-03-28 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
WO2024102730A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and nanoparticle compositions for delivering polynucleotides |
WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
WO2024119074A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticle compositions for cell targeting |
WO2024119039A2 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticles and uses thereof |
WO2024119051A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
CN116270543B (zh) * | 2023-05-19 | 2023-09-26 | 清华大学 | 脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1982004203A1 (en) | 1981-06-04 | 1982-12-09 | Kalat Edwin F | Pressurized container with dispensing pump |
US4778810A (en) | 1987-01-08 | 1988-10-18 | Nastech Pharmaceutical Co., Inc. | Nasal delivery of caffeine |
ES2061416T3 (es) | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
EP2567951B1 (en) * | 2010-04-28 | 2018-09-19 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
CN107082747B (zh) * | 2011-06-08 | 2020-11-20 | 日东电工株式会社 | 用于定向药物输送和增强siRNA活性的化合物 |
WO2013086373A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
AU2013270685B2 (en) * | 2012-06-08 | 2017-11-30 | Nitto Denko Corporation | Lipids for therapeutic agent delivery formulations |
JP6486955B2 (ja) * | 2013-11-18 | 2019-03-20 | アークトゥルス セラピューティクス, インコーポレイテッド | Rna送達のためのイオン化可能なカチオン性脂質 |
-
2015
- 2015-05-11 FI FIEP15724466.6T patent/FI3221293T3/fi active
- 2015-05-11 PT PT157244666T patent/PT3221293T/pt unknown
- 2015-05-11 JP JP2017545520A patent/JP6637988B2/ja active Active
- 2015-05-11 CA CA2968060A patent/CA2968060C/en active Active
- 2015-05-11 RS RS20230231A patent/RS64078B1/sr unknown
- 2015-05-11 PL PL15724466.6T patent/PL3221293T3/pl unknown
- 2015-05-11 HR HRP20230342TT patent/HRP20230342T1/hr unknown
- 2015-05-11 DK DK15724466.6T patent/DK3221293T3/da active
- 2015-05-11 WO PCT/US2015/030218 patent/WO2016081029A1/en active Application Filing
- 2015-05-11 HU HUE15724466A patent/HUE062130T2/hu unknown
- 2015-05-11 NZ NZ732777A patent/NZ732777A/en unknown
- 2015-05-11 ES ES15724466T patent/ES2946110T3/es active Active
- 2015-05-11 KR KR1020177016742A patent/KR102380363B1/ko active IP Right Grant
- 2015-05-11 SI SI201531935T patent/SI3221293T1/sl unknown
- 2015-05-11 CN CN201580073670.9A patent/CN107207428A/zh active Pending
- 2015-05-11 LT LTEPPCT/US2015/030218T patent/LT3221293T/lt unknown
- 2015-05-11 AU AU2015350561A patent/AU2015350561B2/en active Active
- 2015-05-11 EP EP15724466.6A patent/EP3221293B1/en active Active
-
2017
- 2017-05-15 IL IL252291A patent/IL252291B/en unknown
-
2018
- 2018-03-21 HK HK18103903.0A patent/HK1244479A1/zh unknown